Use of the tumor necrosis factor-blockers for Crohn's disease

查看全文 作　　者：Alan BR [1]Thomson;Milli [2]Gupta;Hugh J [3]Freeman

机构地区：[1]Division of Gastroenterology,Department of Medicine,University of Western Ontario;[2]Department of Medicine,University of Alberta;[3]Department of Medicine,University of British Columbia

出　　处：《World Journal of Gastroenterology》索引2012年第18卷第35期,共32页

摘　　要：The use of anti-tumor necrosis factor-therapy for inflammatory bowel disease represents the most important advance in the care of these patients since the publication of the National Co-operative Crohn's disease study thirty years ago.The recommendations of numerous consensus groups worldwide are now supported by a wealth of clinical trials and several meta-analyses.In general,it is suggested that tumor necrosis factor-blockers(TNFBs) are indicated(1) for persons with moderately-severe Crohn's disease or ulcerative colitis(UC) who have failed two or more causes of glucocorticosteroids and an acceptably long cause(8 wk to 12 wk) of an immune modulator such as azathioprine or methotrexate;(2) non-responsive perianal disease;and(3) severe UC not responding to a 3-d to 5-d course of steroids.Once TNFBs have been introduced and the patient is responsive,therapy given by the IV and SC rate must be continued.It remains open to definitive evidence if concomitant immune modulators are required with TNFB maintenance therapy,and when or if TNFB may be weaned and discontinued.The supportive evidence from a single study on the role of early versus later introduction of TNFB in the course of a patient's illness needs to be confirmed.The risk/benefit profile of TNFB appears to be acceptable as long as the patient is immunized and tested for tuberculosis and viral hepatitis before the initiation of TNFB,and as long as the long-term adverse effects on the development of lymphoma and other tumors do not prone to be problematic.Because the rates of benefits to TNFB are modest from a population perspective and the cost of therapy is very high,the ultimate application of use of TNFBs will likely be established by cost/benefit studies. 关键词：肿瘤坏死因子受体阻滞剂溃疡性结肠炎免疫调节剂成本效益糖皮质激素病毒性肝炎临床试验

相关文献

参考文献（183）
引证文献（3）
耦合文献（0）

参考文献(183)

引证文献(3)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Use of the tumor necrosis factor-blockers for Crohn's disease

参考文献(183)

引证文献(3)

用户提示